Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Oct 25 - Oct 30
Always consult a healthcare provider before starting any weight loss treatment
It is being studied in clinical trials, and Lilly has reported positive Phase 3 topline results, but investigational results are not the same as FDA approval
Tirzepatide (Mounjaro, Zepbound) , a dual GIP/GLP-1 receptor agonist, has shown even greater results
Providers that create a smooth path from enrollment to continued therapy may gain stronger demand from pharma manufacturers, health plans, specialty pharmacies and health systems
If those are the side effects getting in your way, your clinician can help you decide if making a switch makes sense
US$ 23.86
US$ 20.91
US$ 21.79
US$ 29.12
US$ 23.53
US$ 24.69
US$ 20.72
US$ 22.44
US$ 26.58
US$ 21.33
US$ 24.53
